Combination Anti-Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Antidiabetic Combination Drugs Market is Segmented Into Type (oral Combinations (Janumet (Sitagliptin and Metformin HCl)) and Insulin Combinations (NovoMix (Biphasic Insulin Aspart), Ryzodeg (Insulin Degludec and Insulin Aspart), and Xultophy (Insulin Degludec and Liraglutide))), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The Market Provides the Value (in USD) for the Above-Mentioned Segments.

Combination Anti-Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Combination Anti-Diabetes Drugs Market Size

Combination Anti-Diabetes Drugs Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 1.21 Billion
Market Size (2030) USD 2.02 Billion
CAGR (2025 - 2030) 10.87 %
Fastest Growing Market Europe
Largest Market North America
Market Concentration High

Major Players

Combination Anti-Diabetes Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Combination Anti-Diabetes Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Combination Anti-Diabetes Drugs Market Analysis

The Combination Anti-Diabetes Drugs Market size is estimated at USD 1.21 billion in 2025, and is expected to reach USD 2.02 billion by 2030, at a CAGR of 10.87% during the forecast period (2025-2030).

Diabetes mellitus increases the risk of viral infections, especially during the period of poor glycemic control. Emerging evidence suggests that it is one of the most common comorbidities in the SARS-CoV-2 infection. The COVID-19 pandemic has substantially impacted the combination anti-diabetes drugs market. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control might improve outcomes and reduce the length of stay in patients with SARS-CoV-2 have underlined the importance of the combination anti-diabetes drugs. 

People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. Moreover, the management and therapy are complex for individuals with diabetes who are acutely unwell with suspected or confirmed COVID-19. Thus, the COVID-19 outbreak increased the combination anti-diabetes drugs market's growth globally.

Generally, metformin is recommended as an initial treatment for patients with diabetes. At the same time, it is recognized that monotherapy does not provide adequate glucose control in a large proportion of patients and that many patients will experience unacceptable side effects with a higher dosage of a single agent. Fixed dose combination antidiabetic medications are a useful and appropriate treatment option in this large group of patients to maintain good glycemic control. The combination drug therapy helps to keep the HbA1c value below 7% for a patient. Combination therapy at low doses minimizes the side effects associated with high dose therapy of either agent and provides additive clinical benefits.

According to International Diabetes Federation (IDF), the adult diabetes population in 2021 is approximately 537 million, and this number is going to increase by 643 million in 2030. The rate of newly diagnosed cases of Type 1 and Type 2 diabetes is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure worldwide are indications of the increasing usage of anti-diabetic drugs. Technological advancements and innovations have increased over the period leading to several modifications either in the drugs or the formulations being developed.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Combination Anti-Diabetes Drugs Industry Overview

The combination anti-diabetes drugs market is moderately consolidated with manufacturers like Novo Nordisk, Merck, Sanofi, Eli Lilly, and others.

Combination Anti-Diabetes Drugs Market Leaders

  1. Boehringer Ingelheim

  2. Sanofi Aventis

  3. Merck & Co., Inc.

  4. Eli Lilly and Company

  5. Novo Nordisk A/S

  6. *Disclaimer: Major Players sorted in no particular order
Combination drugs competitive landscape.png
Need More Details on Market Players and Competiters?
Download PDF

Combination Anti-Diabetes Drugs Market News

July 2022: Glenmark Pharmaceuticals Limited announced that it had launched sitagliptin and its fixed-dose combinations for adults with Type 2 diabetes in India. Glenmark introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT and its variants at an affordable price.

July 2022: European Commission released the Commission Implementing Decision granting marketing authorization under Regulation (EC) No 726/2004 of the European Parliament and the Council for "Sitagliptin/Metformin hydrochloride Accord - sitagliptin / metformin hydrochloride."

Combination Anti-Diabetes Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Oral Combination
    • 5.1.1 Janumet (Sitagliptin and Metformin HCl)
  • 5.2 Insulin Combination
    • 5.2.1 NovoMix (Biphasic Insulin Aspart)
    • 5.2.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    • 5.2.3 Xultophy (Insulin Degludec and Liraglutide)
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Rest of North America
    • 5.3.2 Europe
    • 5.3.2.1 France
    • 5.3.2.2 Germany
    • 5.3.2.3 Italy
    • 5.3.2.4 Spain
    • 5.3.2.5 United Kingdom
    • 5.3.2.6 Russia
    • 5.3.2.7 Rest of Europe
    • 5.3.3 Latin America
    • 5.3.3.1 Mexico
    • 5.3.3.2 Brazil
    • 5.3.3.3 Rest of Latin America
    • 5.3.4 Asia-Pacific
    • 5.3.4.1 Australia
    • 5.3.4.2 China
    • 5.3.4.3 India
    • 5.3.4.4 Indonesia
    • 5.3.4.5 Japan
    • 5.3.4.6 Malaysia
    • 5.3.4.7 Philippines
    • 5.3.4.8 South Korea
    • 5.3.4.9 Thailand
    • 5.3.4.10 Vietnam
    • 5.3.4.11 Rest of Asia-Pacific
    • 5.3.5 Middle East and Africa
    • 5.3.5.1 Saudi Arabia
    • 5.3.5.2 Iran
    • 5.3.5.3 Egypt
    • 5.3.5.4 Oman
    • 5.3.5.5 South Africa
    • 5.3.5.6 Rest of Middle East and Africa

6. MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population
  • 6.2 Type 2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk A/S
    • 7.1.2 Merck
    • 7.1.3 Sanofi
    • 7.1.4 Eli Lilly
    • 7.1.5 Boehringer Ingelheim
  • *List Not Exhaustive
  • 7.2 Company Share Analysis
    • 7.2.1 Novo Nordisk A/S
    • 7.2.2 Merck
    • 7.2.3 Sanofi
    • 7.2.4 Others

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*The report covers a segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Combination Anti-Diabetes Drugs Industry Segmentation

Combination anti-diabetes drugs combine two or more different types of diabetes medicines. Many people with diabetes need combination therapy to keep blood glucose levels within the target range and avoid diabetes-related complications. The Combination Anti-Diabetes Drugs Market is segmented into type (oral combinations (Janumet (Sitagliptin and Metformin HCl)) and insulin combinations (NovoMix (Biphasic Insulin Aspart), Ryzodeg (Insulin Degludec and Insulin Aspart), and Xultophy (Insulin Degludec and Liraglutide))), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.

Oral Combination Janumet (Sitagliptin and Metformin HCl)
Insulin Combination NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Geography North America United States
Canada
Rest of North America
Europe France
Germany
Italy
Spain
United Kingdom
Russia
Rest of Europe
Latin America Mexico
Brazil
Rest of Latin America
Asia-Pacific Australia
China
India
Indonesia
Japan
Malaysia
Philippines
South Korea
Thailand
Vietnam
Rest of Asia-Pacific
Middle East and Africa Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Need A Different Region or Segment?
Customize Now

Combination Anti-Diabetes Drugs Market Research FAQs

How big is the Combination Anti-Diabetes Drugs Market?

The Combination Anti-Diabetes Drugs Market size is expected to reach USD 1.21 billion in 2025 and grow at a CAGR of 10.87% to reach USD 2.02 billion by 2030.

What is the current Combination Anti-Diabetes Drugs Market size?

In 2025, the Combination Anti-Diabetes Drugs Market size is expected to reach USD 1.21 billion.

Who are the key players in Combination Anti-Diabetes Drugs Market?

Boehringer Ingelheim, Sanofi Aventis, Merck & Co., Inc., Eli Lilly and Company and Novo Nordisk A/S are the major companies operating in the Combination Anti-Diabetes Drugs Market.

Which is the fastest growing region in Combination Anti-Diabetes Drugs Market?

Europe is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Combination Anti-Diabetes Drugs Market?

In 2025, the North America accounts for the largest market share in Combination Anti-Diabetes Drugs Market.

What years does this Combination Anti-Diabetes Drugs Market cover, and what was the market size in 2024?

In 2024, the Combination Anti-Diabetes Drugs Market size was estimated at USD 1.08 billion. The report covers the Combination Anti-Diabetes Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Combination Anti-Diabetes Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Diabetes Combination Drugs Industry Report

Statistics for the 2025 Combination Anti-Diabetes Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Combination Anti-Diabetes Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.